Sophiris Bio (NASDAQ:SPHS) Hit With “Buy” Rating From Piper Jaffray, Analysts Expect $7.0000 Stock Price

May 18, 2018 - By Louis Casey

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Investors sentiment increased to 2.8 in Q4 2017. Its up 2.16, from 0.64 in 2017Q3. It is positive, as 2 investors sold Sophiris Bio, Inc. shares while 3 reduced holdings. 8 funds opened positions while 6 raised stakes. 1.87 million shares or 14.89% more from 1.63 million shares in 2017Q3 were reported.

Moreover, Citadel Advsr Ltd Limited Liability Company has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 21,608 shares. Edge Wealth Mgmt Lc reported 2,000 shares. Geode Cap Mngmt Limited has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS). Moreover, Blackrock has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS). Lpl Fincl Limited Liability Company reported 10,000 shares. State Bank Of Montreal Can invested in 0% or 11,210 shares. Architects stated it has 800 shares or 0% of all its holdings. Jpmorgan Chase & Communication holds 0% or 23,401 shares in its portfolio. B & T Cap Dba Alpha Cap reported 0.01% stake. Natl Bank Of America De invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Virtu Fin Limited Liability invested 0.02% in Sophiris Bio, Inc. (NASDAQ:SPHS). Palo Alto Investors Lc reported 247,000 shares stake. Sabby Management Limited Liability reported 0.01% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Bancorp Of New York Mellon Corp invested in 0% or 23,656 shares. 5,000 are owned by Morgan Stanley.

Why Has Piper Jaffray Given Sophiris Bio (NASDAQ:SPHS) a $7.0000 Price Target

The financial firm Piper Jaffray has today has begun coverage on Sophiris Bio (NASDAQ:SPHS) shares, with a “Buy” rating, while setting the TP at $7.0000.

The stock decreased 4.27% or $0.15 during the last trading session, reaching $3.36. About 599,584 shares traded or 126.56% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 26.06% since May 18, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Analysts await Sophiris Bio, Inc. (NASDAQ:SPHS) to report earnings on May, 21. They expect $-0.12 earnings per share, down 33.33 % or $0.03 from last year’s $-0.09 per share. After $-0.11 actual earnings per share reported by Sophiris Bio, Inc. for the previous quarter, Wall Street now forecasts 9.09 % negative EPS growth.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $93.88 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

More important recent Sophiris Bio, Inc. (NASDAQ:SPHS) news were published by: which released: “45 Biggest Movers From Yesterday” on May 16, 2018, also published article titled: “Premarket analyst action – healthcare”, published: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018. More interesting news about Sophiris Bio, Inc. (NASDAQ:SPHS) was released by: and their article: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” with publication date: May 16, 2018.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.